Pericardiotomy in Cardiac Surgery (PRINCE)

July 9, 2025 updated by: Population Health Research Institute

Pericardiotomy in Cardiac Surgery Trial

PRINCE is an international, multicentre, randomized controlled trial of posterior pericardiotomy in patients without a history of atrial fibrillation (AF) or flutter undergoing cardiac surgery.

Study Overview

Detailed Description

Approximately 30% of cardiac surgical patients develop post-operative atrial fibrillation (POAF). Its incidence varies depending on the type of cardiac operation. POAF is associated with short- and long-term adverse events, including mortality, stroke, and heart failure. POAF has also been significantly associated with unplanned hospitalization for heart failure.

During cardiac surgery, pericardial fluid tends to collect posterior to the left atrium. Even small amounts of fluid may trigger atrial arrhythmias. A posterior left pericardiotomy is a surgical procedure that involves cauterizing an opening between the left inferior pulmonary vein and the diaphragm. This procedure may allow for more prolonged drainage of the pericardial fluid into the left pleural space. Recent research evidence found that posterior pericardiotomy was associated with a significantly lower incidence of POAF.

The existing data on posterior pericardiotomy is promising for a reduction in POAF. However, no high-quality study has demonstrated that this reduction improves clinical outcomes in the years after cardiac surgery. The PRINCE trial's long-term follow-up of patients randomized to left posterior pericardiotomy could conclusively demonstrate whether the relationship of POAF to post-discharge clinical outcomes is causal and modifiable.

The PRINCE trial will evaluate the effectiveness and safety of posterior left pericardiotomy in preventing POAF and improving post-discharge clinical outcomes in a broad spectrum of cardiac surgery patients.

The intervention under investigation is left posterior pericardiotomy which is compared to no posterior pericardiotomy during cardiac surgery. The early co-primary outcome is in-hospital POAF, and the late co-primary outcome is the hierarchical composite of time to all-cause death, time to ischemic stroke, time to systemic arterial embolism, time to unplanned hospital visit/readmission for cardiac reasons, and time to atrial fibrillation after index hospital discharge.

The study will enrol 1400 patients from 30 centres, globally. Follow-up visits will be performed in person or by telephone 1 and 6 months post-randomization (+7 days), and then every 6 months (+30 days) until an average follow-up of 5 years for the study participants (estimated to be 4 years after completion of enrolment).

Study Type

Interventional

Enrollment (Estimated)

1400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Vienna, Austria, 1090
    • Ontario
      • Hamilton, Ontario, Canada, L8L 2X2
        • Recruiting
        • Hamilton Health Sciences
        • Contact:
      • Foggia, Italy, 71122
        • Recruiting
        • University of Foggia, Policlinico Foggia
        • Contact:
    • New York
      • New York, New York, United States, 10065
        • Recruiting
        • Weill Cornell Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients greater than or equal to 18 years of age
  • Requiring surgical intervention on the proximal aorta, cardiac valves, and/or coronary arteries
  • Able to provide informed consent

Exclusion Criteria:

  • History of atrial fibrillation or flutter
  • Cardiac surgery procedures not included in the inclusion criteria (planned ventricular assistance device, aortic arch, transplantation surgery)
  • Prior cardiac surgery requiring opening of the pericardium
  • Previous surgical instrumentation of the left pleural cavity
  • Patient undergoing minimally invasive cardiac surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Left Posterior Pericardiotomy Group
The surgeon will perform a left posterior pericardiotomy during the patient's cardiac surgery.
The surgeon will perform a left posterior pericardiotomy while the patient is on cardiopulmonary bypass. A soft channel drain will be put into place at an angle directed toward the posterior pericardium. The surgeon will grasp the pericardium and use cautery to make a 4- to 5-cm opening between the left inferior pulmonary vein and the diaphragm. The previously prepared channel drain is cut to the desired length and placed through the pericardiotomy along the diaphragm and into the pleural space.
No Intervention: No Posterior Pericardiotomy Group
The surgeon will not perform a posterior pericardiotomy during the patient's cardiac surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hierarchical composite of all-cause death, ischemic stroke, systemic arterial embolism, unplanned hospital visit/readmission for cardiac reasons, and atrial fibrillation.
Time Frame: Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
Number of patients with a composite of all-cause death, ischemic stroke, systemic arterial embolism, unplanned hospital visit/readmission for cardiac reasons, and atrial fibrillation events, evaluated using the win ratio (thereby accounting for the difference in importance of these outcomes).
Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
In-hospital post-operative atrial fibrillation
Time Frame: Within 5 days after index cardiac surgery
Number of patients with post-operative atrial fibrillation within the first 5 days postoperatively or up to hospital discharge, whichever occurs first
Within 5 days after index cardiac surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-operative atrial fibrillation (POAF)
Time Frame: Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
Number of patients with post-operative atrial fibrillation
Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
Length of post-operative in-hospital stay
Time Frame: Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
Length of time the patient in hospital after their index cardiac surgery
Over the duration of the follow-up period to a common end date (mean follow-up of 5 years).
Pericardial effusion without tamponade
Time Frame: From index surgery completion to within 30 days of index surgery
Number of pericardial effusions that occur, excluding cardiac tamponade
From index surgery completion to within 30 days of index surgery
Death
Time Frame: From index surgery completion to within 30 days of index surgery
Occurrence of death
From index surgery completion to within 30 days of index surgery
Ischemic stroke or systemic arterial embolism
Time Frame: From index surgery completion to within 30 days of index surgery
Number of ischemic strokes or systemic arterial embolisms
From index surgery completion to within 30 days of index surgery
Hospital readmission or unplanned hospital visit
Time Frame: From index surgery completion to within 30 days of index surgery
Number of hospital readmissions or unplanned hospital visits
From index surgery completion to within 30 days of index surgery
Quality of life assessed by the European quality of life index version 5D (EQ-5D-5L) questionnaire
Time Frame: Over the duration of the follow-up (mean follow-up of 5 years)
The EQ-5D-5L consists of a descriptive system and the EQ visual analogue scale (EQ VAS) scale of 0-100 where the endpoints are labelled 'The best health you can image' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is measured on a 5 point scale: no problems, slight problems, moderate problems, severe problems and extreme problems.
Over the duration of the follow-up (mean follow-up of 5 years)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients with phrenic nerve injuries
Time Frame: Within 30 days of index surgery
Safety outcome
Within 30 days of index surgery
Number of patients with left pleural interventions
Time Frame: Within 30 days of index surgery
Safety outcome
Within 30 days of index surgery
Number of patients with esophageal injuries
Time Frame: Within 30 days of index surgery
Safety outcome
Within 30 days of index surgery
Number of patients requiring re-operation for bleeding
Time Frame: Within 48 hours of index surgery completion
Safety outcome
Within 48 hours of index surgery completion
Number of patients with cardiac tamponade
Time Frame: Within 30 days of index surgery
Safety outcome
Within 30 days of index surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Richard Whitlock, Population Health Research Institute
  • Principal Investigator: Emilie Belley-Côté, Population Health Research Institute
  • Principal Investigator: Mario Gaudino, Weill Medical College of Cornell University
  • Principal Investigator: Sigrid Sandner, Medical University Vienna
  • Principal Investigator: Björn Redfors, Göteborg University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 21, 2024

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2031

Study Registration Dates

First Submitted

June 13, 2024

First Submitted That Met QC Criteria

June 27, 2024

First Posted (Actual)

July 3, 2024

Study Record Updates

Last Update Posted (Actual)

July 14, 2025

Last Update Submitted That Met QC Criteria

July 9, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

Clinical Trials on Left Posterior Pericardiotomy

Subscribe